Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
6.61
+1.03 (18.46%)
May 5, 2026, 11:05 AM EDT - Market open
Evolus Revenue
Evolus had revenue of $73.14M in the quarter ending March 31, 2026, with 6.74% growth. This brings the company's revenue in the last twelve months to $301.79M, up 9.56% year-over-year. In the year 2025, Evolus had annual revenue of $297.18M with 11.61% growth.
Revenue (ttm)
$301.79M
Revenue Growth
+9.56%
P/S Ratio
1.22
Revenue / Employee
$903,566
Employees
334
Market Cap
435.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 297.18M | 30.90M | 11.61% |
| Dec 31, 2024 | 266.27M | 64.19M | 31.76% |
| Dec 31, 2023 | 202.09M | 53.47M | 35.98% |
| Dec 31, 2022 | 148.62M | 48.94M | 49.10% |
| Dec 31, 2021 | 99.67M | 43.13M | 76.29% |
| Dec 31, 2020 | 56.54M | 21.62M | 61.89% |
| Dec 31, 2019 | 34.93M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 676.80M |
| Organogenesis Holdings | 564.17M |
| Aurora Cannabis | 272.13M |
| Akebia Therapeutics | 236.20M |
| Organigram Global | 204.21M |
| Canopy Growth | 203.04M |
| Kamada | 180.46M |
| Anika Therapeutics | 116.26M |
EOLS News
- 18 hours ago - Evolus Earnings Call Transcript: Q1 2026 - Transcripts
- 19 hours ago - Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook - Business Wire
- 23 hours ago - Weight-loss revolution sparks new appetite for aesthetics firms - Reuters
- 20 days ago - Evolus Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 21 days ago - Evolus to Report First Quarter Financial Results on May 4, 2026 - Business Wire
- 5 weeks ago - Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference - Business Wire
- 6 weeks ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Evolus Transcript: Leerink Global Healthcare Conference 2026 - Transcripts